Aliskiren, the first direct renin inhibitor for treatment of hypertension: The path of its development

Journal of Postgraduate Medicine

Volumn 58, Issue 1, 2012, Pages 32-38

  Jadhav, Manoj ^a   Yeola, C ^a   Zope, G ^a   Nabar, A ^a  

^a KEM HOSPITAL   (India)

Author keywords

Aliskiren; direct rennin inhibitor; hypertension

Indexed keywords

ALDOSTERONE; ALISKIREN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BENAZEPRIL; BENAZEPRILAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CGP 38560; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALKIREN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LEPTIN; LOSARTAN; MYOSIN HEAVY CHAIN; RAMIPRIL; REMIKIREN; RENIN; VALSARTAN; WARFARIN; ZANKIREN;

ADD ON THERAPY; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BODY WEIGHT; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HISTORY OF MEDICINE; HUMAN; HYPERKALEMIA; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; PLASMA RENIN ACTIVITY; PROTEINURIA; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RENAL PROTECTION; REVIEW; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ADMINISTRATION, ORAL; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FUMARATES; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84859199698     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.93250     Document Type: Review

References (33)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, Jiang H. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217-23.
2. Shah B, Mathur P. Surveillance of cardiovascular disease risk factors in India: The need and scope. Indian J. Med. Res. 2010;132:634-42.
3. Kumar P, Clarke M. Cardiovascular Disease. In: Green E, Hewat C, editors. Textbook of Clinical Medicine. 6th ed. London: Elsevier Saunders; 2005. p. 725-872.
4. Mende CW. Application of direct renin inhibition to chronic kidney disease. Cardiovasc Drugs Ther 2010;24:139-49.
5. Azizi M, Menard J. Combined blockade of the renin angiotensin system with angiotensin converting enzyme inhibitors and angiotensin II type I receptor antagonist. Circulation 2004;109:2492-99.
6. O'brien E, Barton J, Nusserberger J, Mulchay D, Jensen C, Dicker P, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with thiazide diuretics, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007;49:276-84.
7. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
8. Wood JM, Cumin F. Pharmacology of renin inhibitor and their application to the treatment of hypertension. Pharmacol Ther 1994;61:325-44.
9. Staesson JA, Li Y, Richart T. Oral renin inhibitor. Lancet 2006;368:1449-56.
10. Cagnoni F, Achiri C, Zaninelli A, Ricci AR, Daffra D, D'Ospina D, et al. Blocking the RAAS at different levels: An update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag 2010;6:549-59.
11. Morganti A, Lonati C. Aliskiren: The first direct rennin inhibitor available for clinical use. J of Nephrol 2011;24:541-49.
12. Medilexicon Intrenational Ltd [Homepage on the Internet]. UK; c 2004-2011. Tekturna (aliskiren); [about 2 screens]. Available from http://www.medilexicon.com/drugs/tekturna.php [Last cited on 2011 Feb 16].
13. Solomon S. Effect of the Direct Renin Inhibitor Aliskiren on Left Ventricular Remodeling Following Myocardial Infarction with Left Ventricular Dysfunction ASPIRE. Late Breaker presentation at American College of Cardiology 59th Annual Scientific Sessions [monograph on the internet]. Switzerland: Novartis Global Communications;. Available from: http://www.hugin. info/134323/R/1394184/351134.pdf [Last cited on 2011 Feb 16].
14. Wood D, Simon J, Pyorala K, Amouyel P, Keil U, Ostor E, et al. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997;8:1569-82.
15. Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Ophuis AJ, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: The results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 2010;31:1993-2005.
16. Trimarchi H. Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis 2011;4:41-8.
17. Siragy HM. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag 2011;7:297-313.
18. Jensen C, Herold P, Brunner HR. Aliskiren: The first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410.
19. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen MC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.
20. Australian Public Assessment Report for Aliskiren (as hemifumarate)/Hydrochlorothiazide [monograph on the internet]. Australia Novartis Pharmaceuticals Australia Pty Ltd; 2010. Available from: http://www. tga.gov.au/pmeds/auspar/auspar-rasilez.pdf [Last cited on 2011 Jan 30].
21. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-Transgenic rats. Hypertension 2005;46:569-76.
22. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:417-26.
23. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008;118:984-93.
24. Stucchi P, Cano V, Ruiz-Gayo M, Fernandez-Alfonso MS. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 2009;158:771-8.
25. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46.
26. Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008;9:163-75.
27. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
28. Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-Term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2009;10:157-67.
29. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-7.
30. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43.
31. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-55.
32. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433-6.
33. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Stalin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007;370:221-9.